A notable trend is the licensing of advanced clinical assets from Chinese biotechs to major global pharmaceutical companies for ex-China rights. Deals like Roche licensing Medilink's Phase 3 ADC and AbbVie licensing Reamgen's Phase 2 bispecific antibody signal China's evolution from a market to a source of high-value, late-stage innovation.

After years of focusing on de-risked late-stage products, the M&A market is showing a renewed appetite for risk. Recent large deals for early-stage and platform companies signal a return to an era where buyers gamble on foundational science.

While innovation from China is increasingly integrated into Western pharma pipelines, there's little expectation of outright acquisitions of Chinese companies. The consensus is that licensing a specific asset is far simpler and avoids the significant political and regulatory complexities of a full M&A transaction.

Big Pharma's strategy differs by region: they are willing to acquire innovative US biotechs outright but prefer to only license assets from Chinese companies. This is because Chinese assets can be secured at significantly lower valuations without the complexities of a full M&A transaction, creating an exit dilemma for VCs in China.

Gilead consistently demonstrates an appetite for high-risk, novel science. From pioneering CAR-T (Kite) and new ADCs (Trodelvi) to its latest T-cell engager deal, the company's acquisition history signals a clear preference for cutting-edge platforms rather than safer, later-in-class assets.

AbbVie's deal for ZG006, a Phase 3 T-cell engager, shows the premium on late-stage oncology assets. The $100 million upfront payment for rights outside China, plus significant milestones, underscores a strategy to in-license de-risked candidates to quickly bolster pipelines in competitive areas like small cell lung cancer.

The Simcirzyming and Ipsen deal, valued up to $1.06 billion for a preclinical antibody-drug conjugate (ADC), shows the immense value of promising therapeutic modalities. Technologies like ADCs with features like 'enhanced tumor penetration' can secure massive bio-dollar deals long before human trials, signaling intense competition for next-generation oncology assets.

In a major strategic shift, large pharmaceutical companies are increasingly sourcing their M&A pipeline from China. Chinese assets now account for 30-40% of Big Pharma's early-stage acquisitions, up from single digits just a few years ago, primarily because they are significantly cheaper than US or European equivalents.

Major players are repurposing oncology's T-cell engager technology for autoimmune diseases. Gilead's $1.675B acquisition of Oral Medicines and Sanofi's $1.05B potential deal with Kali Therapeutics highlight a strategic shift to leverage this powerful modality in a new, high-potential therapeutic area.